Health
Amgen's Drug Combo Reduces Lung Cancer Mortality Risk
Amgen announces that a combination of its drug and AstraZeneca’s immunotherapy reduces the risk of death by 58% in patients with aggressive lung cancer.
Coverage timeline — 1 article
CNBC
A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
2026-10-24 14:30 UTC